HLB Group on the Cusp of a New Era with Promising Cancer Drug Developments
HLB Group is currently at a pivotal moment, stepping into a completely new phase, according to Jin In-hye, a director at Elevate Therapeutics, HLBs U.S. subsidiary. In an interview on the 18th at the European Society for Medical Oncology (ESMO 2025) annual conference in Berlin, she stated that the company is on the verge of securing regulatory approval for its new drug, which represents the final piece of its previous chapter, HLB 1.0.
Jin In-hye, the eldest daughter of HLB Group Chairman Jin Yang-gon, is regarded as a strong candidate for the next generation of leadership within the group. Since joining the company in 2021, she has transitioned from the U.S. subsidiary Verismo Therapeutics to her current role at Elevate Therapeutics, where she is responsible for the licensing of liver cancer drugs and the approval process for new treatments.
At ESMO 2025, HLB presented interim analysis results from a Phase 3 clinical trial in China for its immuno-oncology drug Camrelizumab in combination with the targeted therapy Rivoceranib. The results showed a significant improvement in median event-free survival (mEFS), increasing from 19.4 months to 42.1 months, more than doubling the previous rates. Additionally, the major pathological response (MPR) rate improved significantly from 7.5% to 35.1%.
These findings suggest that the combination therapy is effective not only for advanced liver cancer patients but also for those with operable early to mid-stage cancers, potentially expanding treatment options for pre-cancerous stages. Jin expressed confidence in the combination therapys best-in-class potential and emphasized the goal of entering the U.S. market as soon as possible.
She also noted that these research achievements serve as a springboard for HLB’s transition into a global biopharma leader, stating, We are now moving forward.... HLB Group seems poised to revolutionize the treatment landscape for liver cancer and beyond, marking a significant milestone in its corporate journey.
Jin In-hye, the eldest daughter of HLB Group Chairman Jin Yang-gon, is regarded as a strong candidate for the next generation of leadership within the group. Since joining the company in 2021, she has transitioned from the U.S. subsidiary Verismo Therapeutics to her current role at Elevate Therapeutics, where she is responsible for the licensing of liver cancer drugs and the approval process for new treatments.
At ESMO 2025, HLB presented interim analysis results from a Phase 3 clinical trial in China for its immuno-oncology drug Camrelizumab in combination with the targeted therapy Rivoceranib. The results showed a significant improvement in median event-free survival (mEFS), increasing from 19.4 months to 42.1 months, more than doubling the previous rates. Additionally, the major pathological response (MPR) rate improved significantly from 7.5% to 35.1%.
These findings suggest that the combination therapy is effective not only for advanced liver cancer patients but also for those with operable early to mid-stage cancers, potentially expanding treatment options for pre-cancerous stages. Jin expressed confidence in the combination therapys best-in-class potential and emphasized the goal of entering the U.S. market as soon as possible.
She also noted that these research achievements serve as a springboard for HLB’s transition into a global biopharma leader, stating, We are now moving forward.... HLB Group seems poised to revolutionize the treatment landscape for liver cancer and beyond, marking a significant milestone in its corporate journey.
Like
0
Upvote0
- PrevTrump and Xi to Meet at APEC Summit: Focus on U.S.-China Relations
- NextWadiz Reports Dramatic Surge in Game Crowdfunding, Driven by Board Games
김샛*
정말이지 이런뉴스는 올리지 말아주세요.
김홍*
이게 나라냐!!
김한*
정말 대책없네요.
No comments yet.
